Intellia Therapeutics (NTLA) to Release Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is scheduled to be announcing its earnings results before the market opens on Thursday, October 24th. Analysts expect the company to announce earnings of ($1.38) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. Intellia Therapeutics’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.40) EPS. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $20.58 on Thursday. The company has a market capitalization of $1.99 billion, a PE ratio of -3.84 and a beta of 1.76. Intellia Therapeutics has a one year low of $17.09 and a one year high of $34.87. The company’s fifty day moving average price is $21.10 and its 200 day moving average price is $23.03.

Analyst Ratings Changes

Several research analysts recently commented on the stock. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Canaccord Genuity Group reiterated a “buy” rating and issued a $73.00 target price on shares of Intellia Therapeutics in a report on Thursday, June 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a report on Thursday, September 19th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.77.

Insider Buying and Selling

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.00% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.